Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Buying the Pharm(ion)

Celgene Corp. hopes its acquisition of the 95% of Pharmion Corp. it didn't already own for $2.9 billion in cash and stock will broaden its position in the hematology/oncology space by providing it with rights to a number of marketed products, including Vidaza azacitidine and thalidomide, boost its commercial operations in the U.S. and Europe, and enhance its

Read the full 582 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers